January 23, 2024
The op-ed suggests that the Maryland Prescription Drug Affordability Board will somehow inhibit the development of drugs to treat rare diseases. But the fact is that drugs to treat rare diseases and the majority of drugs in the pipeline across the industry are designated as rare disease drugs, which is terrific for patients. Early designation as an orphan product — a drug to treat a disease afflicting small populations — opens up federal money for research and exempts products from federal licensing fees. The sky is the limit for pricing rare disease treatments. See https://healthcareforall.com/wp-content/uploads/2024/01/Horvath-Orphan-Rx-Business-Model.pdf for more information.
Read the full article at marylandmatters.org.Last modified: January 24, 2024